Open an account

Aquestive Therapeutics

AQST · NASDAQ

$4.05+$0.22 (+5.74%)TodayMarket closed ·
Prev close $3.83

AQST analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 11 analysts

Average $9.52 (+135.1% upside)

Low
$6.06
Now
$4.05
High
$11.55

Upgrades and downgrades

The latest rating actions, newest first

AQST analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 24, 2026MaintainsBuy
Piper SandlerNov 7, 2025MaintainsOverweight

The case for and against

Updated Feb 9, 2026

Bull case

Aquestive Therapeutics Inc is poised for positive growth due to its strong positioning in the no-needle epinephrine market, enhanced by the opportunity for both oral and intranasal alternatives. The FDA's recent decision not to require an Advisory Committee meeting for the NDA of Anaphylm has led to a significant 43.77% increase in shares, reflecting investor confidence in the company's product pipeline. Furthermore, the successful submission of a comprehensive data package addressing key regulatory topics suggests a favorable trajectory for potential approval and market expansion.

Bear case

Aquestive Therapeutics faces several fundamental issues contributing to a negative outlook on its stock. The company is at risk of unsuccessful development of its pipeline product AQST-109, coupled with potential revenue erosion from its licensed commercial products, which could adversely affect its financial performance. Additionally, the need for capital raise to strengthen the balance sheet raises concerns about its liquidity and long-term viability in a competitive market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.